How Will Pfizer Leverage External Innovation After BioNTech Jackpot?
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.
You may also be interested in...
The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.
The In Vivo team recently put a spotlight on innovation that might disrupt the pharma and medtech markets. Thinking about novel developments today that will impact the life sciences sector in the near future, we explored interesting new science, the convergence of R&D and technology, as well as what the future of surgery might look like.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2021. Data provided by Biomedtracker.